Yan Lei
Sichuan University
5 Papers
Yan Lei is an academic researcher from Sichuan University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Porous copper- and lithium- doped nano-hydroxyapatite composite scaffold promotes angiogenesis and bone regeneration in the repair of glucocorticoids-induced osteonecrosis of the femoral head.
TL;DR: In this paper, the nano-hydroxyapatite- copper- lithium composite porous scaffold (Cu-Li-nHA) was synthesized to promote osteogenesis and angiogenesis functions to repair GIONFH by regulating the Wnt/β-catenin and HIF-1α/VEGF pathways.
20
Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation
Jing Zhao,Wei Xu,X. Zhuo,Lei Liu,Junlei Zhang,Fengxian Jiang,Yan Lei,Dongsheng Hou,Xiaoyan Lin,Cuiyan Wang,Guobin Fu +10 more
TL;DR: In this paper , the authors used next-generation sequencing (NGS) to find drug mutation targets, which revealed a coiled-coil domain-containing protein 6 (CCDC6)-rearranged during transfection (RET) gene fusion mutation.
Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report
Xin Nie,Ping Zhang,Zhi-Xin Bie,Chenhui Song,Min Zhang,Diansong Ma,Di Cui,Gang Cheng,Hui Li,Yan Lei,Xiaoxing Su,Wendy Wu,Lin Li +12 more
TL;DR: This report supports afatinib can provide potential benefit for NRG1 fusion patients, and RNA-based NGS is an accurate and cost-effective strategy for fusion detection and isoform identification.
2
Identification of a Rare BAIAP2-ROS1 Fusion and Clinical Benefit of Crizotinib in the Treatment of Advanced Lung Adenocarcinoma: A Case Report
TL;DR: This study discovered a novel BAIAP2-ROS1 rearrangement in a 71-year-old non-smoking female patient with stage IVB lung adenocarcinoma, who showed significant tumor reduction until 17 months, who got benefit from targeted therapy.
Distinct genomic features between osteosarcomas firstly metastasing to bone and to lung
Lu Xie,Zhenyu Cai,Hezhe Lu,Fanfei Meng,Xin Zhang,Xiaoxing Su,Yan Lei,Jiu-Hong Xu,Jingbing Lou,Han Wang,Zhiye Du,Yunfan Wang,Yuan Li,Tingting Ren,Jie Xu,Xin-ying Sun,Xiaodong Tang,Wei Qing Guo +17 more
TL;DR: Wang et al. as mentioned in this paper analyzed whole-exome sequencing (WES) data for 38 osteosarcoma with paired samples in different relapse patterns, and they also sought to redefine disease subclassifications based on genetic alterations and correlate these genetic profiles with clinical treatment courses to elucidate potential evolving cladograms.